DG DISPATCH - AAN: Donepezil showed to delay function decline in Alzheimer's
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




DG DISPATCH - AAN: Donepezil showed to delay function decline in Alzheimer's

By Richard Robinson
Special to DG News

SAN DIEGO, CA -- May 5, 2000 -- Donepezil delays functional decline in patients with Alzheimer's disease, according to a study presented at the 52nd Annual Meeting of the American Academy of Neurology held here May 4, 2000.

To test the effect of donepezil on activities of daily living (ADLs) in Alzheimer's disease (AD), Rachelle Doody, MD, of Baylor College of Medicine, in Houston, TX, and colleagues conducted a one-year, double-blind trial in 431 patients with mild-to-moderate AD.

Patients received either placebo or 10 mg donepezil daily. The primary end-point was time to clinically evident functional decline, defined as follows: a decline in the ability to perform one or more ADLs present at baseline; a 20 per cent decline in the ability to perform instrumental ADLs; or an increase in the Clinical Dementia Rating over baseline of 1 or more points.

Instrumental ADLs included use of the telephone, shopping, managing money, and other tasks beyond basic ADLs such as feeding and dressing.

The median time to functional decline was 208 days for placebo and 357 days for donepezil (p=0.002). Loss of the ability to perform instrumental ADLs was the most common reason for reaching the endpoint.

"At the last recorded visit, there was significantly less decline in functional ability in the treated group," said Dr. Doody. "By preserving functional ability in AD patients, treatment with donepezil should reduce caregiver burden," she said.

The study was titled, "Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1- year placebo-controlled functional survival study."

Related Link: donepezil (Aricept).

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities